Home > Cardiology > Myocardial fibrosis measures may help decisions about electronic device implantation

Myocardial fibrosis measures may help decisions about electronic device implantation


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Journal
Journal of the American College of Cardiology
Reuters Health - 25/02/2022 - Assessing myocardial fibrosis by cardiac magnetic resonance (CMR) may be useful in determining which patients can safely receive a cardiac implanted electronic device (CIED), with or without a defibrillator, an observational study suggests. Dr. Francisco Leyva of Aston University in Birmingham, UK and colleagues assessed whether myocardial fibrosis on visual assessment (MFVA) and gray zone fibrosis (GZF) mass predict sudden cardiac death (SCD) and ventricular fibrillation/sustained ventricular tachycardia after CIED implantation. Their study, published in the Journal of the American College of Cardiology, included 700 patients (mean age, 68; 73%, men; 91%, white), including 27 (3.85%) who experienced SCD and 121 (17.3%) who met the arrhythmic endpoint over a median of 6.93 years. MFVA predicted SCD (HR, 26.3; negative predictive value, 100%), as well as the arrhythmic endpoint (subdistribution HR, 19.9; NPV, 98.6%). Compar...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on